Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK.
Maternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, University of Manchester, Manchester M13 9WL, UK.
Int J Mol Sci. 2021 May 28;22(11):5759. doi: 10.3390/ijms22115759.
Metformin is the first-line treatment for many people with type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM) to maintain glycaemic control. Recent evidence suggests metformin can cross the placenta during pregnancy, thereby exposing the fetus to high concentrations of metformin and potentially restricting placental and fetal growth. Offspring exposed to metformin during gestation are at increased risk of being born small for gestational age (SGA) and show signs of 'catch up' growth and obesity during childhood which increases their risk of future cardiometabolic diseases. The mechanisms by which metformin impacts on the fetal growth and long-term health of the offspring remain to be established. Metformin is associated with maternal vitamin B deficiency and antifolate like activity. Vitamin B and folate balance is vital for one carbon metabolism, which is essential for DNA methylation and purine/pyrimidine synthesis of nucleic acids. Folate:vitamin B imbalance induced by metformin may lead to genomic instability and aberrant gene expression, thus promoting fetal programming. Mitochondrial aerobic respiration may also be affected, thereby inhibiting placental and fetal growth, and suppressing mammalian target of rapamycin (mTOR) activity for cellular nutrient transport. Vitamin supplementation, before or during metformin treatment in pregnancy, could be a promising strategy to improve maternal vitamin B and folate levels and reduce the incidence of SGA births and childhood obesity. Heterogeneous diagnostic and screening criteria for GDM and the transient nature of nutrient biomarkers have led to inconsistencies in clinical study designs to investigate the effects of metformin on folate:vitamin B balance and child development. As rates of diabetes in pregnancy continue to escalate, more women are likely to be prescribed metformin; thus, it is of paramount importance to improve our understanding of metformin's transgenerational effects to develop prophylactic strategies for the prevention of adverse fetal outcomes.
二甲双胍是治疗 2 型糖尿病(T2DM)和妊娠期糖尿病(GDM)患者血糖控制的一线药物。最近的证据表明,二甲双胍在怀孕期间可以穿过胎盘,从而使胎儿暴露于高浓度的二甲双胍中,并可能限制胎盘和胎儿的生长。在孕期接触二甲双胍的后代出生时体重小于胎龄(SGA)的风险增加,并在儿童期表现出“追赶”生长和肥胖的迹象,这增加了他们未来患心血管代谢疾病的风险。二甲双胍对胎儿生长和后代长期健康的影响机制仍有待确定。二甲双胍与母体维生素 B 缺乏和抗叶酸样活性有关。维生素 B 和叶酸的平衡对于一碳代谢至关重要,一碳代谢对于 DNA 甲基化和核酸的嘌呤/嘧啶合成至关重要。二甲双胍引起的叶酸:维生素 B 失衡可能导致基因组不稳定和异常基因表达,从而促进胎儿编程。线粒体需氧呼吸也可能受到影响,从而抑制胎盘和胎儿的生长,并抑制哺乳动物雷帕霉素靶蛋白(mTOR)的活性,以进行细胞营养物质的运输。在怀孕期间使用二甲双胍之前或期间进行维生素补充,可能是一种改善母体维生素 B 和叶酸水平、降低 SGA 出生率和儿童肥胖发生率的有前途的策略。GDM 的诊断和筛查标准存在异质性,以及营养生物标志物的短暂性,导致了研究二甲双胍对叶酸:维生素 B 平衡和儿童发育影响的临床研究设计存在不一致性。随着妊娠糖尿病的发病率继续上升,更多的女性可能会被开二甲双胍处方;因此,提高我们对二甲双胍跨代效应的理解,以制定预防不良胎儿结局的预防策略,至关重要。